Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

M0605000

Metformin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,1-Dimethylbiguanide hydrochloride, Metformin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

50 MG
169,00 €

169,00 €

Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Devis pour commande en gros
Toutes les photos(1)

Sélectionner une taille de conditionnement

Changer de vue
50 MG
169,00 €

About This Item

Formule linéaire :
NH2C(=NH)NHC(=NH)N(CH3)2 · HCl
Numéro CAS:
1115-70-4
Poids moléculaire :
165.62
Numéro MDL:
MFCD00012582
Code UNSPSC :
41116107
ID de substance PubChem :
329817811
Nomenclature NACRES :
NA.24

169,00 €

Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Devis pour commande en gros

Qualité

pharmaceutical primary standard

Agence

EP Reference standard

Famille d'API

metformin

Fabricant/nom de marque

EDQM

Pf

223-226 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl[H].CN(C)C(=N)NC(N)=N

InChI

1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H

Clé InChI

OETHQSJEHLVLGH-UHFFFAOYSA-N

Informations sur le gène

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Metformin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Metformin is an antidiabetic agent that reduces blood glucose levels and improves insulin sensitivity. Its metabolic effects, including the inhibition of hepatic gluconeogenesis, are mediated at least in part by activation of the LKB1-AMPK (AMP-activated protein kinase) pathway. Activation of this pathway also appears to be involved in the antiproliferative and proapoptotic actions of metformin in cancer cell lines.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1396310

Metformin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1396309

Metformin hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1331

Metformin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001590

Metformin impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001600

Metformin impurity F, European Pharmacopoeia (EP) Reference Standard

1396331

Metformin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1396342

Metformin Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1505

Metformin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1506

Metformin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1532

Metformin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

BP227

Metformin hydrochloride, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H319

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Yen-Hsiang Chang et al.
Frontiers in endocrinology, 11, 445-445 (2020-08-28)
Background: Plenty of evidence suggested that chronic low-grade inflammation triggered by innate immunity activation contributes to the pathogenesis of type 2 diabetes (T2D). Using the trans-mitochondrial cybrid cell model, we have demonstrated that mitochondria independently take part in the pathological
Emi Kawakita et al.
Molecular cancer research : MCR, 19(1), 61-73 (2020-10-01)
The biological influence of antidiabetic drugs on cancer cells and diabetic cancer patients has not yet been completely elucidated. We reported that a dipeptidyl peptidase (DPP)-4 inhibitor accelerates mammary cancer metastasis by inducing epithelial-mesenchymal transition (EMT) through the CXCL12/CXCR4/mTOR axis.
D Einhorn et al.
Clinical therapeutics, 22(12), 1395-1409 (2001-02-24)
Their complimentary mechanisms of action suggest that a combination of pioglitazone hydrochloride and metformin may have clinically beneficial effects in the treatment of patients with type 2 diabetes. This study was undertaken to assess the efficacy and tolerability of pioglitazone
T W Hale et al.
Diabetologia, 45(11), 1509-1514 (2002-11-19)
The aim of this study was to characterize the milk-to-plasma ratio and infant dose for metformin in breastfeeding women, and to measure plasma concentrations and assess any effects in their infants. We hypothesized that metformin used by mothers is safe
J Radziuk et al.
Diabetes/metabolism research and reviews, 17(4), 250-272 (2001-09-07)
Hepatic glycogen is replenished during the absorptive period postprandially. This repletion is prompted partly by an increased hepatic uptake of glucose by the liver, partly by metabolite and hormonal signals in the portal vein, and partly by an increased gluconeogenic
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique